What is Harmony Biosciences Holdings EV-to-EBITDA?
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Harmony Biosciences Holdings's enterprise value is $1,714.2 Mil.
Harmony Biosciences Holdings's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was $237.9 Mil. Therefore, Harmony Biosciences Holdings's EV-to-EBITDA for today is 7.20.
The historical rank and industry rank for Harmony Biosciences Holdings's EV-to-EBITDA or its related term are showing as below:
HRMY'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -79.36 Med: 12.14 Max: 6148.23
Current: 7.2
During the past 7 years, the highest EV-to-EBITDA of Harmony Biosciences Holdings was 6148.23. The lowest was -79.36. And the median was 12.14.
HRMY's EV-to-EBITDA is ranked better than 51.11% of 495
companies
in the Biotechnology industry
Industry Median: 8.09
vs HRMY: 7.20
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Harmony Biosciences Holdings's EV-to-EBITDA
For the Biotechnology subindustry, Harmony Biosciences Holdings's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Harmony Biosciences Holdings's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Harmony Biosciences Holdings's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Harmony Biosciences Holdings's EV-to-EBITDA falls into.
Harmony Biosciences Holdings's current Enterprise Value is $1,714.2 Mil.
Harmony Biosciences Holdings's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $237.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Harmony Biosciences Holdings's PE Ratio (TTM) for today is calculated as:
Harmony Biosciences Holdings's share price for today is $34.50.
Harmony Biosciences Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.620.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Harmony Biosciences Holdings EV-to-EBITDA Related Terms
Thank you for viewing the detailed overview of Harmony Biosciences Holdings's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HRMY has been successfully added to your 